Summary Malignant human breast tumours contain high levels of prostaglandin E2 (PGE2). However, the mechanisms controlling PGE2 production in breast cancer are unknown. This in vitro study investigates the capacity for PGE2 synthesis and metabolism in several human breast cancer cell lines and early passage human breast fibroblasts and seeks to identify potential regulatory factors which may control these pathways. Basal PGE2 production rose up to 30-fold 
Elevated levels of prostaglandin E2 (PGE2) have been widely reported in malignant human breast tumours (Bennett, 1979; Rolland et al., 1980; Karmali et al., 1983) as well as experimental murine mammary tumour models (Tan et al., 1974) . Furthermore, these high levels are often associated with tumours exhibiting high metastatic potential (Rolland et al., 1980; Karmali et al., 1983) . Similarly, in vitro studies with tissue explants or primary cultures of human breast tumour cells have also demonstrated increases in PGE2 production from malignant tissue compared with benign or normal (Watson and Chuah, 1985; . Although the pathophysiological significance of this correlation in the context of a role for PGE2 in breast cancer growth and progression is unclear, several studies with murine mammary tumour models indicate that PGE2 may indeed play a multifunctional role in controlling growth, metastasis and host immune responses (Foecking et al., 1982; Fulton and Heppner 1985; Fulton et al., 1991) . PGE2 has been shown to be mitogenic for normal human and murine mammary epithelial cells (Bandyopadhyay et al., 1987; Balakrishnan et al., 1989) but inhibits both human breast cancer cell growth (Fentiman et al., 1984) and DNA synthesis in human breast fibroblasts (Patel and Schrey, 1992) . Both stromal (Fernig et al., 1990) and epithelial (Bandyopadhyay et al., 1987) Notwithstanding the considerable evidence supporting a role for PGE2 production in breast tumour biology, neither the nature of the cell types involved nor the paracrine factors controlling PGE2 levels in human breast tumour tissue are known. In the present study we sought to address these questions by monitoring PGE2 production in several human breast cancer cell lines and breast stromal fibroblasts in response to various putative agonists of both phospholipase A2 and cyclo-oxygenase, the two rate-limiting enzymes in PG synthesis.
Under the combined influence of the inflammatory mediators IL-li and BK breast fibroblasts represent a potentially rich source of PGE2. In contrast, under the various conditions employed we were unable to detect any PGE2 production in the majority of breast cancer cell lines investigated, with the exception of two hormone-independent lines (MDA-MB-231 and Hs578T). Net PGE2 production by breast fibroblasts was greatly reduced in co-cultures with breast cancer cells (T47-D or . This appeared to be due to metabolic inactivation by PG dehydrogenase present in the cancer cells.
Materials and methods [5,6,8,11,12,14,15(n) Dr M O'Hare (Haddow Laboratories, Sutton, UK) and Dr J Taylor-Papadimitriou (Imperial Cancer Research Fund Laboratories, London, UK). CLF-90-1 cells were established in our own laboratory from tissue fragments of a primary ductal infiltrating carcinoma of the breast and display a typical epithelial morphology in culture. CLF-90-1 cells are oestrogen and progesterone receptor-positive and exhibit growth stimulation and growth inhibition in response to oestradiol and medroxyprogesterone acetate respectively. All these cell lines were maintained as previously described (Patel and Schrey, 1990 ) in Eagle's minimal essential medium (EMEM) supplemented with glutamine (2 mM) and bicarbonate (4.5 mM) containing 20 mM Hepes (pH 7.4) and 5% fetal calf serum (FCS) with the exception of BT-20 which was grown in 10% FCS.
Human breast fibroblasts Human breast fibroblasts (HBFs) were prepared and maintained in culture as previously described (Patel and Schrey, 1992 In studies employing breast cancer cell lines, cell numbers were determined by releasing and counting cell nuclei in a Coulter counter as previously described (Patel and Schrey, 1990 Release of PGE2 into the culture media was measured using a specific radioimmunoassay as previously described (Kelly et al., 1986) . The antisera employed was raised to the methyl oxime of PGE2. At the end of each experiment aliquots of the culture media were derivatised at room temperature overnight with equal volumes of methyloximating reagent (Kelly et al., 1986) Endothelin immunoradiometric assay The production of ET-1 by MCF-7 cells was measured using a specific solid phase-based sandwich assay in 96-well microtitre plates as previously described (Patel and Schrey, 1995) . The sensitivity of the assay is 0.5pmoll1' with percentage cross-reactivities for ET-1, big ET-1, ET-2 and ET-3 being 100, 0.01, 100 and 50 respectively.
[3H]PGE2 metabolism T47-D cells grown to 70% confluence in 12-well plates were serum starved for 4 h and then incubated for 24 h in 1 ml medium with or without TPA (10 nM 
Results
PGE2 production in different human mammary cell lines PGE2 production was monitored in ten different human breast mammary cell lines: three stromal fibroblast lines (HBF-10,-11,-12); four hormone-dependent cancer cell lines (MCF-7, T47-D, ZR-75-1 and CLF-90-1) and three hormone-independent lines (BT-20, MDA-MB-231 and Hs578T). Under optimal conditions in the presence of 10 fM arachidonate, basal PGE2 production increased up to 30-fold in breast fibroblasts, whereas with the exception of MDA-MB-231 cells, no changes in PGE2 production were observed in the presence of exogenous substrate in any breast cancer cell lines (Table I) . IL-il, appeared to be a potent inducer of (Table I ). In a separate study TPA also enhanced PGE2 production in breast fibroblasts in the presence of arachidonate, the respective values for arachidonate alone, TPA alone and arachidonate plus TPA being: 357 ± 33, 58 + 7 and 3799 ± 604 pg ml-' (mean ± s.d., n = 3). Cell lines unresponsive to IL-l or TPA (e.g. MCF-7, T47-D) with regard to PGE2 production exhibited evidence of functional receptors for these agonists as demonstrated by increases in ET-1 production in response to both agonists (MP Schrey and KV Patel, unpublished results). Cyclic AMP (cAMP) elevation is essential for IL-lp-stimulated PGE2 production in certain cell types (Burch and Connor, 1992) . However, PGE2 production by either MCF-7 cells or T47-D cells remained unresponsive to IL-lp in the presence of cAMP elevating agonists such as cholera toxin or forskolin. PGE2 synthesis was also undetectable in MCF-7 and T47-D cells incubated with either oestradiol or epidermal growth factor (MP Schrey and KV Patel, unpublished results). Transient pretreatment of breast fibroblasts with indomethacin reduced basal PGE2 production in the presence of 10 tLM arachidonate but did not prevent subsequent induction of PGE2 production by IL-lp (Figure 1 ). Previous studies in various cell types including fibroblasts have shown IL-lp induction of cyclo-oxygenase 2 (COX-2) activity and PGE2 production to be inhibited by glucocorticoids (Raz et al., 1990; Crofford et al., 1994) . In the present study, dexamethasone treatment also inhibited IL-ll-induced PGE2 production in breast fibroblasts (Figure 1 ).
Synergistic interactions between IL-1p and inflammatory peptides during.fibroblast PGE2 production In the absence of exogenous arachidonate, optimal IL-illinduced PGE2 production in breast fibroblasts was greatly enhanced in the presence of BK (Figure 2a) . Similarly, synergism in IL-ip pretreated fibroblasts was also observed in response to the B, BK-receptor agonist des-Arg9-BK or ET-1 (Figure 2b ). Apparent cyclo-oxygenase activity as measured by PGE2 production in the presence of 10 iM arachidonate was unaffected by BK, des-Arg9-BK or ET-1, whereas PGE2 synthesis in IL-lp-treated fibroblasts was enhanced 5.7-fold in the presence of exogenous substrate (Figure 2b ).
Apparent inhibition of PGE2 production in stromal/epithelial co-cultures In view of the heterogenous nature of primary cell or tissue cultures previously employed to monitor PGE2 production in human breast tumours, we have also examined the effect of stromal/epithelial co-cultures on PGE2 production. The effect of overnight co-culture with T47-D cells on basal and IL-illstimulated PGE2 production by fibroblasts is shown in Figure 3a . PGE2 production in T47-D cells alone is undetectable (compare Table I ), whereas basal and IL-lp-stimulated production by breast fibroblasts was inhibited by 83% and 42% respectively when co-cultured with T47-D cells ( Figure  3a) . The lack of effect of T47-D cell-conditioned medium on fibroblast PGE2 production compared with that observed in co-cultures is shown in Figure 3b . An inhibitory effect of T47-D cells per se on both basal and IL-lll-stimulated PGE2 production in fibroblasts is clearly evident (Figure 3b ). Basal fibroblast PGE2 production was similarly inhibited in cocultures with T47-D cells or MCF-7 cells (Figure 3c ). To * * ** investigate a potential metabolic capacity of breast cancer cells to modulate net PGE2 production in co-culture, the recovery of exogenous PGE2 added to T47-D cells was monitored. A temporal decline in exogenous PGE2 recovered from T47-D cell cultures was observed (Figure 3 insert) (Schrey et al., 1992a) . Another novel paracrine action of ET-1 is the stimulation of PGE2 production by breast fibroblasts as described above (see Figure 2b) . To investigate the potential for a bidirectional paracrine cross-talk between epithelial and stromal cells, the effect of PGE2 on ET-1 production by MCF-7 cells was also assessed. During a 24 h incubation, basal ET-1 production by MCF-7 cells was increased from 30.1 ± 0.3 to 70.9 ± 6.9 fmol 10-6 cells (P<0.001) in the presence of PGE2 (1 SAM). 
Discussion
Several studies have reported elevated levels of PGE2 in malignant human breast tumour tissue (Bennett, 1979; Rolland et al., 1980; Karmali et al., 1983; Chuah, 1985, 1992) . However, the cell types involved and the regulatory mechanisms controlling PGE2 levels in breast tumours are unknown. A major limitation of in vitro studies employing breast tumour tissue or even primary cell cultures derived from tumour tissue is the presence of non-malignant cells which may obscure the true capacity of PG synthesis by the cancer cells. Indeed, the stromal fibroblast component may represent a significant contribution to tumour cell mass given the marked desmoplasia often associated with breast cancer. The availability of established human breast cancer cell lines and early passage human breast fibroblasts provide simplified experimental models which permit the study of PG production under various culture conditions. Two important criteria essential for the control of optimal PGE2 production are the regulation of substrate availability and the capacity to metabolise free arachidonate to PGE2. Furthermore, phospholipase A2 and cyclo-oxygenase, the two rate-limiting enzymes involved, are themselves subject to regulation by a variety of paracrine factors. In this respect it is desirable to know if the activity of these enzymes is constitutively expressed in breast cancer cells and fibroblasts and whether a potential exists for their induction and/or activation.
In the present study apparent constitutive cyclo-oxygenase activity, as measured by PGE2 production in the presence of exogenous substrate was only detectable in one (MDA-MB-231) out of seven breast cancer cell lines investigated. In contrast, under the same conditions all breast fibroblast lines consistently exhibited a high capacity for PGE2 production. Although such arachidonate metabolism is often characteristic of mammalian fibroblasts derived from various tissues this is to our knowledge the first report of PGE2 production in human breast stromal cells. Recently an inducible form of cyclo-oxygenase, COX-2, has been described whose activity and expression is enhanced by IL-lp and phorbol ester and inhibited by dexamethasone (Crofford et al., 1994) . Despite possessing receptors for IL-lp (Paciotti and Tamarkin, 1988) Interleukin 11B also caused large increases in breast fibroblast PGE2 production in the absence and presence of exogenous substrate. Hence in addition to cyclo-oxygenase induction, the cytokine may also increase phospholipase A2 activity as described in other cell types (Lyons-Giordano et al., 1993) . In the absence of added arachidonate, the fibroblast PGE2 response to IL-lp was greatly enhanced by BK and ET-1, both of which are known to stimulate phospholipase A2 in several cell types. Since cyclo-oxygenase activity in breast fibroblasts appeared to be unaltered by these peptides, this synergism between peptide and cytokine may be partly mediated by the concerted activation and induction of phospholipase A2 and cyclo-oxygenase respec- tively. Similar synergistic interactions between these inflammatory mediators have been described previously for the regulation of PG synthesis in decidual (Schrey et al., 1992b; Schrey and Hare, 1992) , gingival (Lerner and Modeer, 1991) and synovial fibroblasts (Bathon et al., 1989) . The observed inhibition of IL-ip action in breast fibroblasts by dexamethasone would also be characteristic of and consistent with a role for COX-2 induction by the cytokine in these cells as recently described during IL-lp-stimulated PG production in other cell types (Crofford et al., 1994) .
Control of PGE2 in breast cancer MP Schrey and KV Patel 1417 The significance of this stromal cell PGE2 production in response to inflammatory kinins and cytokines with regard to breast tumour biology is at present uncertain. Nonetheless IL-lp-mediated increases in matrix-metalloproteinase activity in the tumour microenvironment may be subject to negative regulation by PGE2 (Case et al., 1990; Mackay et al., 1992) . We have previously proposed a mediatory autocrine role for PGE2 in the inhibition of breast fibroblast growth by BK (Patel and Schrey, 1992) . Interestingly, in this regard BK has been reported to inhibit the in vivo growth of spontaneous mammary tumours and sarcomas in mice (Mashiba and Matsunaga, 1985) and SV-40-induced fibrosarcomas in hamsters (Koppelmann et al., 1978) . Stromal PGE2 may also exert an inhibitory paracrine influence on breast cancer cell growth as evidenced by its anti-proliferative action on MCF-7 cells (Fentiman et al., 1984) .
Notwithstanding an equivocal role for inflammatory mediators such as IL-1p and BK in breast cancer, tumour stroma generation exhibits many parallels with the processes involved in inflammation, connective tissue remodelling and wound repair, including infiltration of cytokine-producing host immune cells (Whalen, 1990) . Furthermore, a number of studies indicate a local activation of the kallikrien-kinin cascade in tumours from several different cancers (Maeda et al., 1988; Karlsrud et al., 1991; Matsumura et al., 1991) .
A role for ET-1 as a paracrine mitogen for breast stromal tissue has been recently implicated (Baley et al., 1990; Schrey et al., 1992a) . This action may partially account for the extensive desmoplasia seen in breast tumours (Yamashita et al., 1991 (Yamashita et al., , 1992 . In the present study we have presented evidence for a novel potential paracrine cross-talk between epithelial and stromal breast tumour components involving ET-1 and PGE2. Thus, ET-1 stimulates PGE2 production by breast fibroblasts and PGE2 stimulates ET-1 production by breast cancer cells. Whether such a positive feedback loop might contribute to the elevated levels of PGE2 and ET-1 seen in breast tumours and to the control of tumour stroma generation remains speculative.
In an attempt to investigate a potential paracrine control of breast stromal cell PG production, co-cultures of T-47D (or MCF-7) cells and breast fibroblasts were employed.
Under these co-culture conditions both basal and IL-lpstimulated stromal cell PGE2 production appeared to be inhibited. Experiments indicating the lack of an inhibitory effect of T47-D cell-conditioned media on fibroblast PGE2 and a reduced recovery of exogenous PGE2 from T47-D cell cultures are consistent with metabolic inactivation of PGE2 by the breast cancer cells. This interpretation was further supported by the metabolic capacity of T47-D cells to readily convert PGE2 to 1 5-keto-PGE2. 1 5-Hydroxy-PG dehydrogenase, which catalyses this conversion, is considered to be the key enzyme controlling the biological inactivation of prostaglandins. Although this enzyme appears to be ubiquitous in mammalian tissues, the specific cell types responsible for prostaglandin catabolism are uncertain. Clearly, the regulation of this enzyme may also play an important role in determining breast tumour tissue PGE2 levels. The production of 15-keto-PGE2 in T47-D cells was stimulated by the phorbol ester TPA and inhibited by cycloheximide treatment. In accordance with a recent study using the leukaemia HL-60 cell line to investigate 15-hydroxy PG dehydrogenase regulation (Xun et al., 1991) (Cheng et al., 1993) . The potential for similar hormonal regulation of this enzyme in breast tissue requires investigation. Indeed, PGE2 levels in DMBA-induced rat mammary tumours increase following ovariectomy (Foecking et al., 1982) and prostaglandins have also been implicated in mastalgia associated with premenstrual syndrome (Budoff, 1986) .
Despite the association of elevated PGE2 with a malignant metastatic phenotype, the value of breast tumour PGE2 levels as a prognostic indicator remains uncertain. Although initial studies suggested a poor prognosis in patients with high PG levels (Bennett et al., 1977) others have shown either no relationship to established prognostic indices (Wilson et al., 1980; Watson et al., 1987) or a correlation with favourable prognostic factors (Karmali et al., 1983; Watson and Chuah, 1985; Fulton et al., 1982) . These disparate findings could be attributed to various factors including: differences in the techniques employed; substrate availability; and tissue handling as well as the labile nature of both tissue PGE2 levels per se and the rapid turnover of the enzymes regulating PGE2 production and metabolism. Interestingly, a recent study measuring immunoreactive membrane-associated phospholipase A2 in breast tissue reported high expression in malignant vs benign or normal tissue (Yamashita et al., 1993) .
Whether this overexpression of phospholipase A2 in malignant breast tissue is instrumental in causing elevated PGE2 levels in these tumours remains to be established.
In summary, this study identifies the breast stromal fibroblast as a potential source for PGE2 production in breast tumours. Putative paracrine factors which may regulate this arachidonate metabolism include cytokines and peptides such as IL-1p, kinins and endothelin. We are currently engaged on a comparative study to determine whether fibroblasts derived from normal or malignant breast tissue exhibit any differential capacity for PGE2 synthesis. Since the capacity for PGE2 production in breast cancer cells appears to be restricted to oestrogen receptor-negative cell lines with an invasive phenotype, whether the cancer cells per se contribute towards prostaglandin synthesis may depend on the specific histological class of tumour. Finally, metabolic inactivation by the cancer cells may also play an important regulatory role in the control of breast tumour PGE2 levels.
Abbreviations HBF, human breast fibroblast; PG, prostaglandin; PGEM, prostaglandin E metabolite; IL-1p, interleukin 1p; BK, bradykinin; ET-1, endothelin-1; TPA, 12-0-tetradecanoylphorbol-13-acetate; PKC, protein kinase C; COX-2, cyclo-oxygenase 2; TLC, thin layer chromatography; EMEM, Eagle's minimal essential medium; FCS, fetal calf serum.
